Phenylephrine

證據等級: L5

預測適應症: 3 個

Phenylephrine: From Established Decongestant Use to Nasal Cavity Disease

One-Sentence Summary

Phenylephrine is a topical α1-adrenergic agonist whose original indication record is not captured in this evidence pack (drug currently not marketed under this registry, 0 licenses). The TxGNN model assigns very high confidence (99.97%) to Nasal Cavity Disease, and the evidence pack's own rationale notes this largely reflects an already-established clinical use (nasal decongestion) rather than a truly novel hypothesis — supported by 8 clinical trials and 8 publications currently identified.

Quick Overview

Item	Content
Original Indication	Not on file — no license/indication data recorded (drug not marketed)
Predicted New Indication	Nasal Cavity Disease
TxGNN Prediction Score	99.97%
Evidence Level	L2
Germany Market Status	✗ Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed formal mechanism-of-action documentation (DrugBank field) was not retrieved for this record (flagged as data gap DG002). However, the evidence pack's own repurposing rationale supplies the pharmacological basis: phenylephrine is a selective α1-adrenergic receptor agonist that acts directly on nasal mucosal vascular smooth muscle, producing vasoconstriction and reducing mucosal swelling and congestion — a mechanism that maps directly onto the "nasal cavity disease" prediction.

Importantly, this is not a novel repurposing hypothesis in the usual sense. As explicitly noted in the evidence pack, the empty original_indications field reflects a data-collection gap rather than a true absence of this indication — phenylephrine's decongestant role is long-established clinically (e.g., in co-phenylcaine nasal spray). The TxGNN prediction here functions more as a confirmation of known pharmacology than a discovery of new therapeutic potential.

The supporting evidence is a mix of direct (Grade A: co-phenylcaine nasal spray trials) and class-analogous (Grade B: oxymetazoline, another α-agonist decongestant, used comparably in sinus surgery) data, which together are mechanistically coherent even though several retrieved trials (e.g., esmolol/lidocaine, cocaine/xylometazoline comparisons) do not actually involve phenylephrine and were graded C as low-relevance noise from the retrieval process.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03380715	NA	Completed	106	Co-phenylcaine (contains phenylephrine) nasal spray vs nebulization for decongestion/local anesthesia prior to nasoendoscopy — directly relevant (Grade A)
NCT03228914	Phase 4	Completed	20	Topical oxymetazoline vs epinephrine (same-class α-agonists) compared for bleeding control/surgical visualization in sinus surgery — class-level evidence (Grade B)
NCT00562120	Phase 2	Completed	21	Four-way crossover RCT on nasal congestion after allergen challenge; whether phenylephrine was the actual study drug is unconfirmed from public data (Grade B)
NCT06457100	Phase 1/2	Active, not recruiting	60	IV esmolol vs lidocaine for recovery quality after sinus surgery — no phenylephrine used (Grade C)
NCT03962634	Phase 2	Terminated	3	Kovanaze (tetracaine/oxymetazoline) nasal mist vs articaine for dental anesthesia — no phenylephrine (Grade C)
NCT04104789	Phase 2	Withdrawn	0	Withdrawn duplicate of the Kovanaze vs articaine trial — no data contribution (Grade C)
NCT02993770	NA	Unknown	120	Endoscopic vs external dacryocystorhinostomy technique comparison — no confirmed phenylephrine use (Grade C)
NCT06443255	Phase 3	Completed	16	Cocaine vs lidocaine/xylometazoline vs saline for intranasal analgesia before nasotracheal intubation — no phenylephrine (Grade C)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15854186	2005	RCT	Int J Clin Pract	Double-blind RCT: cophenylcaine spray vs placebo before flexible nasendoscopy — minimal pain/discomfort in both arms, no significant difference found
25133491	2014	RCT	PLoS One	Triple-blind RCT of topical tranexamic acid on bleeding/surgical field quality during FESS in chronic rhinosinusitis
9780066	1998	Cohort	Int J Pediatr Otorhinolaryngol	Acoustic rhinometry of nasal cavity/nasopharynx geometry before and after adenotonsillectomy
40899890	2025	Cohort	Vestnik Otorinolaringologii	Safety/efficacy evaluation of Polydexa spray with phenylephrine in acute rhinosinusitis
37184554	2023	Review	Vestnik Otorinolaringologii	Differential diagnosis of chronic nasal cavity disease after surgery and topical antibiotic therapy (incl. phenylephrine-containing Polydexa)
37970776	2023	Review	Vestnik Otorinolaringologii	Pathogenetic approach to treatment of inflammatory diseases of the nose and paranasal sinuses
7378007	1980	Case Report	Arch Ophthalmol	Case report: cocaine toxicity during dacryocystorhinostomy, with one patient also reacting to intranasal phenylephrine
1375136	1992	In-vitro	Clin Otolaryngol Allied Sci	In-vitro study of drug effects (including nasal-active agents) on ciliary beat frequency

Germany Market Information

No marketing authorization records are available in this evidence pack — market_status is 未上市 (Not marketed) with 0 licenses on file for this drug entity.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-drug interaction data were not retrievable for this record — flagged as blocking data gap DG001.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Evidence level L2 is supported by one directly relevant Grade A trial/RCT (co-phenylcaine nasal spray) plus consistent class-level evidence from comparator α1-agonists, but this largely confirms an already-established decongestant use rather than a novel indication, and critical safety/regulatory documentation is entirely missing.

To proceed, the following is needed:

TFDA/BfArM package insert — warnings, contraindications, DDI data (DG001, Blocking)
Confirmed mechanism-of-action documentation from DrugBank (DG002, High)
Clarification of true original indication/license status, given the drug shows 0 current market authorizations
Verification of the actual study drug in NCT00562120, as public materials do not confirm phenylephrine was the intervention
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.